PFMD

What PFMD does

PFMD (Patient Focused Medicines Development) is a Brussels-headquartered, non-profit collaborative initiative founded in 2013 and hosted by The Synergist ASBL. It operates as a global, non-competitive coalition of 60+ member organizations spanning large pharmaceutical companies, medical technology firms, patient advocacy groups, academic institutions, and regulators, all focused on embedding patient engagement across the medicines development lifecycle. The organization provides no commercial products; instead it distributes frameworks, tools, and training under a Creative Commons license through its integrated PEM Suite (Patient Engagement Management Suite), which encompasses PE Quality Guidance (PEQG), How-To Guides, a co-created training program, Fair Remuneration / FMV tools, legal templates, monitoring tools, and the Patient Experience Data Navigator. Its secondary platform, Synapse, aggregates the global patient engagement ecosystem into a single map and networking layer.

The business model is membership-funded: pharmaceutical, medtech, patient, academic, and regulatory organizations join and pay recurring contributions that finance the coalition's operations, tool development, and events such as the Patient Engagement Open Forum (PEOF). Distribution is primarily self-serve via the PEM Suite website (pemsuite.org) and Synapse (patientengagement.synapseconnect.org), supplemented by direct membership engagement, working groups, and community events. Customer concentration is moderate: while marquee pharma members (Novartis, Roche, J&J, GSK, AstraZeneca, Merck, Sanofi, MSD, Takeda, Astellas, UCB, Gilead, Servier) are individually prominent, membership is spread across 60+ organizations across multiple stakeholder types, and there is no ARR or contract-value disclosure.

Operationally PFMD runs with 11-50 employees and publishes annual impact reports, with the most recent 10-year Impact Report documenting a decade of program continuity. Strategic priorities for the next phase include geographic expansion into Asia, deepening vertical coverage in medtech and digital health, opening the coalition to investor/ESG audiences, and scaling the Synapse network and Clinical Trial Information Network as ecosystem infrastructure.

Name

PFMD

Legal name

PFMD (Patient Focused Medicines Development)

Website

https://patientfocusedmedicine.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Membership Fees: PFMD operates on membership contributions from pharmaceutical companies, medical technology companies, patient organizations, academic institutions, and other healthcare stakeholders. The not-for-profit collaborative initiative is hosted by The Synergist and funded through member organizations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

PFMD provides a global, non-competitive coalition that delivers tools, frameworks, training, and a digital network to help pharmaceutical, medical technology, patient, academic, and regulatory organizations plan, execute, and measure patient engagement across the medicines development lifecycle. Its flagship PEM Suite bundles quality guidance, how-to guides, training, legal and fair remuneration tools, monitoring instruments, and a patient experience data navigator, complemented by the Synapse engagement network.

Product overview

PFMD offers a comprehensive platform-plus-modules architecture centered around the PEM Suite (Patient Engagement Management Suite), which provides an integrated toolbox for systematic patient engagement. The core platform includes Synapse, a global patient engagement network and map that aggregates the ecosystem. The product portfolio encompasses specialized modules for quality guidance (PEQG), how-to guides, patient engagement training, fair remuneration tools (FMV), monitoring and learning tools, patient experience data tools, legal/contractual tools, and thematic initiatives like the Patient Engagement Open Forum (PEOF), Clinical Trial Information Network, and the PE Global Landscape Mapping & Networking Tool. These products work together to enable organizations to plan, assess, and execute patient engagement initiatives across the medicines development lifecycle.

Differentiator

Problem solved

Functional benefit

Brands

• PEM Suite: An integrated toolbox for systematic patient engagement offering practical tools to plan, assess and execute any patient engagement initiative.
• Synapse
• Patient Engagement Open Forum (PEOF)
• Patient Engagement Training
• Fair Remuneration Tools

Products and services

• PEM Suite (Patient Engagement Management Suite)

Quantifiable outcome

• Trials using patient-centric designs are 19% more likely to be launched compared to those that do not (Economist Intelligence Unit study)
• +4 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

17 partnerships are on record, tiered core and secondary.

• The SynergistcoreStrategic or Co-development PartnerThe Synergist ASBL is the parent organization hosting PFMD. The Synergist comprises multiple health initiatives including Patient Focused Medicines Development, Break Dengue, Maternal Health Alliance, and others. It provides operational infrastructure, governance, and administrative support to PFMD.
• NovartiscoreStrategic or Co-development PartnerMajor pharmaceutical member actively supporting PFMD initiatives. Novartis has implemented PFMD training programs with strong leadership support, demonstrating commitment to embedding patient engagement culture. Global Head of Patient Partnership participates in PFMD governance.
• Johnson & JohnsoncoreStrategic or Co-development PartnerPharmaceutical member contributing to patient engagement training and initiatives with PFMD.
• RochecoreStrategic or Co-development PartnerRoche's Global Head of Patient Partnership is actively involved in PFMD efforts to advance patient involvement in drug development.
• GlaxoSmithKline (GSK)coreStrategic or Co-development PartnerGSK has implemented patient engagement initiatives including support programs that proved valuable during the pandemic, working with PFMD frameworks.
• European Patients' Forum (EPF)coreStrategic or Co-development PartnerLeading European patient organization co-leading PARADIGM project and contributing to patient engagement frameworks and standards.
• EURORDIScoreStrategic or Co-development PartnerEuropean organization representing rare disease patients, contributing expertise to PFMD patient engagement initiatives.
• PARADIGM (IMI Project)coreStrategic or Co-development PartnerMulti-stakeholder IMI project co-led by EPF and EFPIA, providing framework for structured patient engagement. PFMD participates in this initiative to develop metrics and meaningful engagement frameworks.
• EUPATIcoreStrategic or Co-development PartnerEU PATI (European Patients' Academy on Therapeutic Innovation) shares common objectives with PFMD in supporting patient engagement. PFMD and EUPATI collaborate on training and capacity building.
• PACTsecondaryStrategic or Co-development PartnerBulgarian national patients organization whose Secretary General contributes to Global Remuneration Principles development.
• Cutting Edge InformationsecondaryStrategic or Co-development PartnerData analytics firm providing market-based approaches to Fair Market Value determination for patient remuneration. Expert contributor to FMV methodology development.
• Edwards LifesciencessecondaryStrategic or Co-development PartnerMedical technology company working with PFMD to advance patient engagement in the medtech sector.
• FasterCures/Milken InstitutesecondaryStrategic or Co-development PartnerResearch organization focused on health innovation, contributing expertise to patient engagement ecosystem.
• ICHOMsecondaryStrategic or Co-development PartnerInternational Society for Pharmacoeconomics and Outcomes Research collaborates on patient-centered outcomes measurement.
• Ludwig Boltzmann Gesellschaft (LBG)secondaryStrategic or Co-development PartnerAustrian research funding body with Open Innovation in Science Center engaging patients in research priority setting through crowdsourcing initiatives.
• IHI (Innovative Health Initiative)coreStrategic or Co-development PartnerSuccessor to IMI, the world's largest Public Private Partnership in life sciences with €2.4 billion budget. IHI aims to include patients at every stage of research projects, building on IMI's patient engagement work.
• Youth Cancer Europe (YCE)secondaryStrategic or Co-development PartnerPatient organization co-leading development of Global Principles on patient remuneration with PFMD.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• ICHOM (International Consortium for Health Outcomes Measurement): Non-profit coalition developing standardized patient-centered outcome sets. Named PFMD member; directly comparable in building frameworks that make patient-relevant outcomes measurable across the healthcare ecosystem.
• National Health Council (NHC): US-based coalition of patient organizations and industry partners advancing patient-centric health policy. Named PFMD member; directly comparable as a multi-stakeholder convener on patient engagement standards and quality.
• FasterCures (Milken Institute): Action tank focused on patient engagement and health R&D acceleration. Named PFMD partner; directly comparable in mission to make patient engagement systematic across the development lifecycle.
• TransCelerate BioPharma: Non-profit consortium of major pharma companies collaborating on R&D efficiency, including patient-centric trial initiatives. Comparable multi-stakeholder pharma coalition model targeting similar sponsors with shared tools and frameworks.
• Clinical Trials Transformation Initiative (CTTI): Multi-stakeholder coalition (FDA, pharma, academia, patient reps) that designs and drives adoption of clinical trial quality and efficiency practices. Highly comparable in structure, membership, and mission to PFMD's clinical trial workstreams.
• EUPATI (European Patients' Academy on Therapeutic Innovation): Patient-led training academy on medicines R&D that overlaps directly with PFMD's training and capacity-building mission. PFMD and EUPATI explicitly collaborate, indicating they serve the same member base and complement rather than duplicate.
• EURORDIS – Rare Diseases Europe: European patient organization coalition representing rare disease patients in medicines development and policy. Both a PFMD member and a peer working on patient engagement capacity-building and fair remuneration principles.
• NIHR INVOLVE / Centre for Engagement and Dissemination: UK national program funding and supporting public involvement in health and social care research. Named PFMD member; a comparable national-scale infrastructure for patient engagement in research with overlapping methods and frameworks.

Broad incumbents

• Innovative Health Initiative (IHI / former IMI): €2.4B public-private partnership in life sciences with patient engagement as a stated cross-cutting priority. Larger and more capitalized than PFMD, but operates in the same multi-stakeholder convening space where PFMD's frameworks are deployed.
• Drug Information Association (DIA): Global life-sciences knowledge-exchange organization with active programs in patient engagement, regulatory science, and clinical operations. Operates at much larger scale than PFMD with overlapping pharma, regulator, and patient audiences.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/PFMDwithPatient
• YouTubeyoutube.com/channel/UCKaaYzLwY9_ZEQZAz6r9KKg
• Facebookfacebook.com/PFMDwithPatient
• LinkedInbe.linkedin.com/showcase/patient-focused-medicines-development-pfmd

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PFMD